海南医学院学报2024，Vol.30Issue(22)：1735-1743,9.DOI:10.13210/j.cnki.jhmu.20240402.002
CDK4/6抑制剂联合氟维司群二线治疗Luminal型晚期乳腺癌的Meta分析
Combinatorial CDK4/6 inhibitors and fulvestrant in second-line therapy for luminal advanced breast cancer:A meta analysis
摘要
Abstract
Objective:To assess the efficacy and safety of CDK4/6 inhibitors in conjunction with fulvestrant in the second-line therapy for luminal-type advanced breast cancer.Methods:We meticulously selected randomised controlled trials evaluating the combination therapy of CDK4/6 inhibitors and fulvestrant for luminal-type advanced breast cancer from January 2010 to January 2024.Studies were identified through extensive searches of databases including the PubMed,Web of Science,Embase,CNKI,Wanfang Data,and VIP.Data were then analyzed utilizing RevMan5.4 and Stata17.0 to perform a comprehensive meta-analysis.Results:Our analysis incorporated data from 8 pertinent studies,encompassing 5 randomized controlled trials with a total of 2 466 participants.The meta-analysis indicated that,compared with the placebo plus fulvestrant cohort,the CDK4/6 inhibitor plus ful-vestrant regimen enhanced progression-free survival[HR=0.51,95%CI(0.46,0.56),P<0.000 01]and overall survival[HR=0.73,95%CI(0.65,0.83),P<0.000 01]in patients with breast cancer.Additionally,the CDK4/6 inhibitor plus fulvestrant group experienced an higher incidence of adverse effects such as neutropenia,anemia,leukopenia,platelet count decline,and fa-tigue when compared to the control group with statistically significant difference(P<0.05).Conclusion:CDK4/6 inhibitors com-bined with fulvestrant significantly prolongs both progression-free and overall survival instances in patients with luminal-type ad-vanced breast cancer compared with placebo plus fulvestrant therapy.The regimen is predominantly characterized by hematologic toxicities including leukopenia,neutropenia,anaemia,platelet drop,and fatigue.However,the prevalence of high-grade(grade 3 or above)adverse events remains within a controllable threshold,thereby enhancing the therapeutic index and conferring a net clini-cal benefit.关键词
CDK4/6抑制剂/乳腺癌/内分泌耐药/有效性/安全性/Meta分析Key words
Cyclin-dependent kinases inhibitor proteins/Breast neoplasms/Endocrine resistance/Efficacy/Safety/Meta-analysis分类
医药卫生引用本文复制引用
张慧慧,刘琳,盛佳丽,郑少江..CDK4/6抑制剂联合氟维司群二线治疗Luminal型晚期乳腺癌的Meta分析[J].海南医学院学报,2024,30(22):1735-1743,9.基金项目
This study was supported by Hainan Clinical Medical Center Funding Project(QWYH2021276) 海南省临床医学中心资助项目(QWYH2021276) （QWYH2021276）
